Novo Nordisk A/S Common Stock (NY:NVO)

Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up ↗

Topics Economy Stocks

September 17, 2025

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.

Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?

Why Novo Nordisk Stock Popped Today ↗

September 17, 2025

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial ↗

September 17, 2025

Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky

September 17, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ ↗

September 16, 2025

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study ↗

September 16, 2025

Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky

September 17, 2025

These dividend payers cranked up their payouts over the past decade, and they could do it again.

Topics Fraud Lawsuit

2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now ↗

September 17, 2025

The Wegovy maker reported positive results from a clinical trial of a next-generation obesity treatment.

Why Novo Nordisk Stock Popped Today ↗

September 16, 2025

Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition

September 16, 2025

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...

Via MarketMinute

Topics Earnings Economy Intellectual Property

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy ↗

September 16, 2025

FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days.

Via Benzinga

Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over? ↗

September 16, 2025

Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow.

Via Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗

September 16, 2025

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Via Benzinga

3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗

September 16, 2025

In an otherwise hot stock market, healthcare stocks are underperforming.

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO

September 16, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO

September 16, 2025

The weight loss drug market may reach $95 billion within five years.

Topics Fraud Lawsuit

Here Is My Top Stock Pick Among the Weight Loss Industry Leaders ↗

September 16, 2025

Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

What's Going On With Novo Nordisk Shares Monday? ↗

September 15, 2025

Via Benzinga

Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact ↗

September 15, 2025

EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients.

Via Benzinga

Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition

September 15, 2025

Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance....

Via MarketMinute

Topics Economy Intellectual Property

Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook

September 15, 2025

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Why Novo Nordisk Stock Popped Today ↗

September 15, 2025

A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO

September 15, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO

September 15, 2025

NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

Topics Fraud Lawsuit

September 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

September 15, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks ↗

September 13, 2025

FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA...

Via Benzinga

NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

September 12, 2025